Pathology Outlines

Home > Stains & CD markers > ARID1A

Stains & CD markers
ARID1A

Author: Nat Pernick, M.D.

Last author update: 1 February 2014

Last staff update: 1 September 2023

Copyright: 2003-2025, PathologyOutlines.com, Inc.

PubMed Search: ARID1A

Table of Contents

Cite this page: Pernick N. ARID1A. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/stainsarid1a.html. Accessed January 15th, 2025.

Definition / general

AT Rich Interactive Domain 1A (SWI-like) tumor suppressor gene at 1p36.11 encodes BAF250A, a member of the SWI/SNF ATP-dependent chromatin-remodeling complexes (J Gynecol Oncol 2013;24:376)
Involved in tissue development and cellular differentiation
Inactivation of components of chromatin-remodeling complex are associated with malignancy
- Most ARID1A somatic mutations are frame-shift or nonsense mutations that contribute to mRNA decay and loss of protein expression
- 5% of ARID1A mutations are in-frame insertions or deletions (indels) that involve only a small stretch of peptides (Neoplasia 2012;14:986)

Clinical features

Bladder: mutations associated with poor prognosis urothelial carcinomas (PLoS One 2013;8:e62483)
Breast: loss of expression associated with carcinoma ( Tumour Biol 2014;35:4813)
- May be due to promoter hypermethylation (PLoS One 2013;8:e53931)
Cervix: loss of expression a poor prognostic factor (Hum Pathol 2013;44:1365)
- Loss in 31% of adenocarcinoma / adenosquamous carcinoma (Int J Gynecol Cancer 2012;22:208)
- Endocervical-type mucinous borderline tumors may be related to endometrioid tumors based on mutation and loss of expression of ARID1A (Int J Gynecol Pathol 2012;31:297)
Colorectum: mutated in 39% of microsatellite instability (MSI) cancers (Int J Cancer 2014;135:611 Dec 31)
Esophagus: mutated in 15% of Barrett's related high grade dysplasia or esophageal adenocarcinoma (Oncogene 2014;33:347)
- Loss of expression in 12-16% of Barrett's related dysplasia / esophageal adenocarcinoma
Kidney: loss of expression a poor prognostic factor in clear cell carcinoma (Am J Pathol 2013;182:1163)
Neuroblastoma: mutations of ARID1A or ARID1B in 11%; poor prognostic factor (Nat Genet 2013;45:12)
Ovary: loss of expression in 52% of clear cell carcinoma (Mod Pathol 2014;27:983)
- Loss of expression may be early event in endometriosis-associated ovarian carcinoma (Int J Mol Sci 2013;14:18824, Int J Clin Exp Pathol 2012;5:642, Int J Gynecol Cancer 2012;22:1310)
Stomach: loss of expression in gastric carcinoma associated with poor prognosis (PLoS One 2012;7:e40364, Virchows Arch 2012;461:367)
Uterus: loss of expression may play important role in tumor progression of endometrioid carcinoma (Am J Surg Pathol 2013;37:1342)
- Loss of expression in 46% of high grade endometrioid carcinomas; associated with mismatch repair deficiency and normal p53 expression (Mod Pathol 2014;27:255, Mod Pathol 2013;26:1525)
Loss of expression in 20% of endometrial clear cell carcinomas, does not predict prognosis (Mod Pathol 2013;26:1101)